摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

litocholic acid, sodium salt | 13284-86-1

中文名称
——
中文别名
——
英文名称
litocholic acid, sodium salt
英文别名
sodium lithocholate;NaLCh;sodium;(4R)-4-[(3R,5R,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoate
litocholic acid, sodium salt化学式
CAS
13284-86-1
化学式
C24H39O3*Na
mdl
——
分子量
398.562
InChiKey
AECTYFQKWPXOSR-DGMAEHPPSA-M
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.18
  • 重原子数:
    28
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.96
  • 拓扑面积:
    60.4
  • 氢给体数:
    1
  • 氢受体数:
    3

SDS

SDS:a4da1242eed10a9f0b60b62df46f94d0
查看

反应信息

  • 作为反应物:
    描述:
    litocholic acid, sodium salt 在 phosphate buffer 、 3α-HSDH from Pseudomonas paucimobilis 、 sodium pyruvateβ-烟酰胺腺嘌呤二核苷酸 作用下, 以 环己烷乙酸乙酯 为溶剂, 反应 48.0h, 以70%的产率得到(5beta)-3-氧代-胆烷-24-酸
    参考文献:
    名称:
    新型假单胞菌羟脯氨酸羟类固醇脱氢酶催化的区域特异性氧化还原
    摘要:
    据报道,一种新的3α-羟基类固醇脱氢酶(3α-HSDH)催化了羟基的制备规模区域和立体特异性氧化以及几种C 21胆汁酸在C(3)处的酮基功能降低。从古朴假单胞菌的细胞中分离出的粗酶显示存在另一种包含仲醇脱氢酶(SADH)的酶馏分,该酶已用于回收辅因子。
    DOI:
    10.1016/s0040-4020(98)01111-9
  • 作为产物:
    描述:
    参考文献:
    名称:
    Dansyl-Labeled Cholic Acid as a Tool To Build Speciation Diagrams for the Aggregation of Bile Acids
    摘要:
    Bile acids (BAs) are a family of natural steroids biosynthesized from cholesterol in the liver that tend to form aggregates in solution. A fluorescent derivative of cholic acid, namely 3 alpha-Dns-ChA, was employed as a reporter to establish the speciation diagrams of the most abundant BAs that can be found mainly in three microenvironments, solution, and primary and secondary aggregates. The developed methodology is based on the analysis of the combined steady-state and time-resolved experiments performed on 3 alpha-Dns-ChA whose emission behavior was found to be strongly medium dependent. In particular, speciation diagrams of sodium glycocholate (NaGCh), sodium taurocholate (NaTCh), sodium chenodeoxycholate (NaCDCh), sodium glycochenodeoxycholate (NaGCDCh), sodium deoxycholate (NaDCh), and sodium ursodeoxycholate (NaUDCh) were successfully built up.
    DOI:
    10.1021/jp308624h
点击查看最新优质反应信息

文献信息

  • MODIFIED RELEASE FORMULATIONS OF A BUPROPION SALT
    申请人:OBEREGGER Werner
    公开号:US20080038348A1
    公开(公告)日:2008-02-14
    The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
    本发明涉及药物组合物、配方和药物,包括一种丁螺环酮盐,特别是包括有效量的丁螺环酮氢溴酸盐的缓释片剂,以及使用丁螺环酮盐来制备治疗疾病的药物。
  • FILM COMPRISING ACTIVE DRUGS
    申请人:Maibach Todd
    公开号:US20090004254A1
    公开(公告)日:2009-01-01
    The present invention is related to the composition and methods of manufacture of orally-dissolvable, edible films as a vehicle for the non-invasive administration of active drugs through the mucosal tissues of the oral cavity. The films include a water soluble film-forming polymer such as pullulan. Methods for producing the films are also disclosed.
    本发明涉及口腔黏膜组织非侵入性给药的载体,即可口服溶解、可食用薄膜的组成和制造方法。该薄膜包括水溶性薄膜形成聚合物,例如泊尔乐糖。本发明还公开了制造该薄膜的方法。
  • BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS
    申请人:WILLIAMS Parry Robert
    公开号:US20080075774A1
    公开(公告)日:2008-03-27
    Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.
    本文描述了Bupropion hydrobromide配方及其用于治疗疾病的使用。
  • Rapid-Melt Compositions and Methods of Making Same
    申请人:Cherukuri S. Rao
    公开号:US20100010101A1
    公开(公告)日:2010-01-14
    The present invention provides a novel rapid-melt pharmaceutical composition comprising a binder, a super emulsifier, a diluent/bulking material; and an active ingredient. The present invention also provides a rapid-melt bead composition comprising a binder having a melting point from about 20 to about 90° C., an emulsifier; a diluent/bulking material; and an active ingredient. Further, the present invention provides a chew tablet composition comprising a binder; an emulsifier having a melting point of greater than about 40° C.; a diluent/bulking material; and an active ingredient. Methods of making the disclosed compositions are also described.
    本发明提供了一种新型的快速熔化制剂,包括粘合剂、超级乳化剂、稀释剂/增容材料和活性成分。本发明还提供了一种快速熔化珠子制剂,包括熔点在约20至约90℃之间的粘合剂、乳化剂、稀释剂/增容材料和活性成分。此外,本发明还提供了一种咀嚼片制剂,包括粘合剂、熔点大于约40℃的乳化剂、稀释剂/增容材料和活性成分。还描述了制备所述组合物的方法。
  • Modified release formulations of a bupropion salt
    申请人:Oberegger Werner
    公开号:US20070027213A1
    公开(公告)日:2007-02-01
    The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
    本发明涉及制药组合物、配方和药物,包括丁丙腈酮盐,特别是包含有效量的丁丙腈酮羟溴盐的改良释放片剂,以及使用丁丙腈酮盐制备治疗疾病的药物。
查看更多